Ligand Pharmaceuticals
LGND
350 hedge funds and large institutions have $3.89B invested in Ligand Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 70 funds opening new positions, 111 increasing their positions, 115 reducing their positions, and 30 closing their positions.
282% more call options, than puts
Call options by funds: $6.71M | Put options by funds: $1.76M
133% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 30
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
11% more funds holding
Funds holding: 314 → 350 (+36)
7% more capital invested
Capital invested by funds: $3.63B → $3.89B (+$254M)
0.18% less ownership
Funds ownership: 104.7% → 104.52% (-0.18%)
3% less repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 115
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$51.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$26.5M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$25.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.4M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$133M |
| 2 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$36M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$17.5M |
| 4 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
-$14.9M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$13.5M |
LGND Hedge Fund Activity: Q4 2025 in Review
350 of the 7,941 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2025, worth a combined $3.89B — up 7% from $3.63B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new LGND positions and 30 closed out — a net gain of 40 holders — while 111 added to existing stakes and 115 trimmed.
The largest buyer was Franklin Resources, adding an estimated $51.2M. The largest seller was Macquarie Group, exiting entirely with an estimated $133M sold.
- 350 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2025, up from 314 in Q3 2025.
- Funds reported $3.89B of Ligand Pharmaceuticals stock for Q4 2025, up 7% quarter-over-quarter.
- 70 funds opened new Ligand Pharmaceuticals positions in Q4 2025 and 30 closed out, a net change of +40 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2025 was Franklin Resources, an estimated $51.2M added.
- The largest Ligand Pharmaceuticals seller in Q4 2025 was Macquarie Group, an estimated $133M sold.
Based on aggregated 13F filings for Q4 2025.